Ulta Salon Wows Investors and Analysts With Updated Guidance
Shares of Ulta Beauty saw a handy gain on Thursday after the company raised its guidance for the third quarter and fiscal year in conjunction with its analyst and investor conference.
Shares of Ulta Beauty saw a handy gain on Thursday after the company raised its guidance for the third quarter and fiscal year in conjunction with its analyst and investor conference.
After Fluidigm announced preliminary results for its third quarter on Wednesday, investors sent the shares sharply lower.
Ocular Therapeutix and Regeneron are attempting to develop a sustained release formulation of aflibercept that is suitable for advancement into clinical development.
Argus has launched coverage of GrubHub with a Buy rating and a price target that implies upside of almost 30%.
CSX Corp. (NASDAQ: CSX) reported fiscal third-quarter financial results after markets closed on Wednesday. With macroeconomic and energy headwinds taking their toll on markets, CSX delivered results consistent with what analysts were expecting. The…
The U.S. Securities and Exchange Commission (SEC) recently announced that Deutsche Bank (NYSE: DB) has agreed to pay a $9.5 million penalty for failing to properly safeguard material nonpublic information generated by its research…
Fortinet shares slid in Wednesday’s session after the company released its preliminary third-quarter financial results.
Delta Air Lines is scheduled to release its third-quarter financial results on Thursday before the markets open.
JetBlue's traffic in September increased almost 11% from September 2015, on a capacity increase of nearly 8%.
Shares of IntelliPharmaCeutics soared after the company reported a new licensing deal with Mallinckrodt.
Short interest in these selected social media stocks was mixed for the most recent settlement date.
The September 30 short interest data have been compared with the previous figures, and short interest for the selected cybersecurity stocks was mixed.
Accelerated Pharma intends to price less than 2 million shares in the range of $8 to $10 for an initial public offering valued up to more than $21 million.
The September 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest was mixed.
The markets have been retreating, begging the question whether the recent tech rally is over. The latest short interest data might suggest that it is.
The September 30 short interest data have been compared with the previous figures, and short interest for the selected oil stocks was mixed.
If a single failed clinical trial can mean disaster for a biotech stock, then short sellers can argue for a stock implosion down the road.
Barracuda Networks Inc. (NYSE: CUDA) reported fiscal second-quarter financial results after markets closed on Tuesday. The company said that it had $0.21 in earnings per share (EPS) on $87.9 million in revenue. Thomson Reuters…
Biostar Pharmaceuticals Inc. (NASDAQ: BSPM) is watching its shares nearly double on Tuesday after the company announced that it is releasing a new product line to treat respiratory irritation and inflammation. Specifically, Biostar is launching…
The SEC has announced that in its fiscal year 2016 the agency filed 868 enforcement actions, a new single year high for such actions.